Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country's ...

David Ricks, the CEO of Mounjaro and Zepbound maker Eli Lilly, explained why these medications are so expensive on the "In Good Company with Nicolai Tangen" podcast this week. 1. Time and money ...

Eli Lilly's weight-loss drugs include Mounjaro and Zepbound.Sandy Huffaker for The Washington Post/Getty Images Weight-loss drugs such as Ozempic and Zepbound cost $900 to $1,500 for a month's supply.

Lilly reported earlier this month that its revenue in the latest fiscal quarter jumped 45% with its new products contributing more than $3.1 billion, driven mainly by strong demand for Mounjaro ...

The makers of Mounjaro, Lilly UK, said patient safety is its “top priority”. Lilly UK stressed: “Regulatory agencies conduct extensive independent assessments of the benefits and risks of ...

In February last year, CEO David Ricks told Reuters that Lilly expects to launch Mounjaro in India as early as 2025. Mounjaro, chemically known as tirzepatide, is currently sold in the UK and ...

The makers of Mounjaro, Lilly UK, said patient safety is its “top priority”. Lilly UK stressed: “Regulatory agencies conduct extensive independent assessments of the benefits and risks of ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on Monday.

Mounjaro, manufactured by Lilly, may have emerged as the newest and most effective treatment option after a victory over Novo Nordisk’s Ozempic in clinical trials. For some patients, injectables ...